August 21, 2026 - Trends

Vero Advances Biological Age Testing

Scoreboard.
Vero
Vero

Biological age is just a number.

Zooming in. Predictive health company Vero is readying Compass, a clinical and consumer platform deriving organ aging and disease risk from a single blood test. Licensing AI-powered proteomic IP from Stanford, it aims to make longevity scoring more actionable.

Scoreboard. A core indicator of healthspan, biological age emerged as a proxy of good health — prompting operators across preventative health, supplements, and fitness to develop their own diagnostic scoring methods.

But, the body’s systems don’t always operate in sync. Analyzing cellular function, Vero delivers individual scores for brain, liver, kidneys, and more, identifying disease risks before they can impact other organs — and take years off life.

Internalizing. Believing people are “only as healthy as [their] oldest organ,” CEO Paul Coletta sees its OrganAge scoring as key to earlier targeted intervention. Piloting its consumer platform with Biograph clinics ahead of 2027 launch, its field is already expanding, with Superpower launching nine-system diagnostics this summer via a partnership with the Buck Institute.

Looking ahead: Gamifying the gap between chronological and biological age was longevity 1.0. Helping consumers see and act on what’s driving it will define the next age.

Ryan Deer
Ryan Deer
Strategic intelligence for the future of health.

We break down how fitness, wellness, and healthcare are converging — and what it means for business, culture, and capital.

No thanks.